Introduction
============

Of all neurological conditions, stroke is one of the most devastating disease^[@bib1])^. Almost one half of stroke survivors remain disabled, and a seventh requires the institutional care^[@bib2])^. The INR standardizing the prothrombin time has been accepted as a sensitive and reliable marker of coagulation abnormalities^[@bib3])^, and is widely used in the management of patients receiving anticoagulation treatment^[@bib4],\ [@bib5])^. Changes in blood coagulation function may accelerate blood clot formation or may influence clinical outcome in acute ischemic stroke patients with atrial fibrillation (AF), especially under the anticoagulation therapy^[@bib6],\ [@bib7])^. Yet, it is critical to understand the potential mechanism, which is related to the self-protection in an attempt to avoid excessive brain injury after acute ischemic stroke^[@bib8])^.

Some studies found that the increased admission INR was an independent predictor of poor clinical outcomes in trauma, acute decompensated heart failure, and acute pulmonary embolism patients^[@bib9]--[@bib11])^. Some researchers explored the relation between admission INR and acute infarct volume in ischemic stroke patients with preadmission warfarin use^[@bib12])^. However, the instantaneous change of INR after cerebral ischemia was not understood. On the other hand, the prognostic value of INR among ischemic stroke patients without AF or without anticoagulation has not been investigated so far. We assumed that the INR would also have a prognostic value in ischemic stroke patients without AF. Thus, the goal of the current study was to explore the clinical significance and prognostic value of admission INR on adverse stroke outcomes including all-cause death, recurrent stroke, combined end point, and poor functional outcome in patients with acute ischemic cerebrovascular events based on the China national stroke registry phase II.

Methods
=======

Study Design and Participants
-----------------------------

The population used for this study was from China National Stroke Registry II (CNSR II). The CNSR II design was described in detail previously^[@bib13])^. Briefly, the CNSR II launched in 2012 is a nationwide initiative to establish a reliable national stroke database for evaluating stroke care delivery in clinical practice and identifying areas that need further improvement compared with CNSR I in 2007^[@bib14])^. Of 25,018 patients participated in CNSR II, 14,782 patients without anticoagulation therapy were eligible for the current study after excluding hemorrhagic stroke (*n* = 3,246), medical history of AF or diagnosis of AF at discharge (*n* = 1,822), anticoagulation therapy during hospitalization (*n* = 100), missing or extreme INR value (an INR \> 5.00 is considered as extreme value, *n* = 2,880), and loss to 1-year follow-up (*n* = 2,008) (**[Supplementary Fig. 1](#F2){ref-type="fig"}**). The study was approved by the central Institutional Review Board at Beijing Tiantan Hospital, in compliance with the Declaration of Helsinki. Every participant provided signed informed consent before his/her participation.

![Flow chart showing the patients selection from China National Stroke Registry II AF indicates atrial fibrillation; INR, international normalized ratio.](jat-26-378-g002){#F2}

Data Collection
---------------

Trained research coordinators in each hospital collected the baseline data including patient demographics, vascular risk factors, stroke severity, lab test, medication use, complication, and diagnosis at discharge. The vascular risk factors included the history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, and moderate or heavy alcohol consumption (≥ 2 standardized alcohol drinks per day). The hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, any use of continuous antihypertensive drug for more than 2 weeks before the onset of cerebrovascular diseases, or self-reported history of hypertension. The dyslipidemia was defined as serum triglyceride ≥ 150 mg/dL, low-density lipoprotein cholesterol ≥ 130 mg/dL, high-density lipoprotein cholesterol ≤ 40 mg/dL, any use of lipid-lowering drugs, or any self-reported history of dyslipidemia. The diabetes mellitus was defined as fasting glucose level ≥ 7.0 mmol/L (126 mg/dL), the nonfasting glucose concentration ≥ 11.1 mmol/L (200 mg/dL) with classic symptoms of hyperglycemia or hyperglycemic crisis, any use of glucose-lowering drugs, or any self-reported history of diabetes mellitus. The height and weight were measured with participants wearing a scrub suit and no shoes, and then the body mass index (BMI) was calculated by dividing the weight in kilograms at the square of height in meters.

Measurements of INR
-------------------

The venous blood was drawn from patients who fasted within the first 24 h of admission for routine laboratory measurements including INR. The blood samples were obtained, preserved, and processed in a manner recommended by the clinical site laboratory\'s policies and procedures. The 3.2%citrate tubes are used and filled properly to maintain a blood/citrate ratio of 9/1. INR was measured on a STA-R EVOLUTION automated coagulation analyzer (Diagnostica Stago, Asnières, France) with an international sensitivity index of approximately 1.0 and using HemosIL RecombiPlasTin 2G as reagent (Instrumentation Laboratory, Bedford, MA, USA). The reference range of INR was roughly 0.9--1.1 in all clinical laboratories.

Study Outcomes
--------------

The participants were followed up by telephone interview by trained research personnel who were blinded to patient baseline clinical status. The patients were asked standardized follow-up questions 12 months after the onset of stroke. The study outcomes included the all-cause mortality, stroke recurrence, and poor functional outcome. Death was confirmed either by the death certificates from local citizen registries or from the treating hospitals. If such records were unavailable, the death was confirmed if it was reported on 2 consecutive follow-up contacts with ≥ 2 different proxies. The recurrent stroke included the ischemic stroke, intracranial hemorrhage, and subarachnoid hemorrhage. The recurrent end points of the stroke comprised fatal and nonfatal stroke. We also evaluated the composite of death or recurrent stroke in the prognostic analysis. The poor functional outcome was defined as the modified Rankin Scale ranging from 3 to 6.

Statistical Analysis
--------------------

The subjects were divided into the following three groups based on the reference range of INR - low INR (\< 0.9), medium INR group (0.9--1.1), and high INR (\> 1.1). The baseline characteristics were compared between the three INR groups. The continuous variables were expressed as mean (SD) or median (interquartile range, IQR) values, and compared using the analysis of variance or Kruskal--Wallis test. The categorical variables were expressed as frequency (percent), and compared using the chi-square test.

The multivariable logistic regression models were used to assess the association of INR with 12-month clinical outcomes in stroke patients. The covariates in the multivariable analysis included the age, sex, history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, moderate or heavy alcohol consumption, BMI, admission NIHSS and mRS scores, pneumonia, antihypertensive, antidiabetic and lipid-lowing therapy, as well as the time from onset to the blood sampling. The odds ratios (ORs) were calculated with confidence intervals (CIs) of 95% for low and high INR groups compared to the medium group.

To explore the association between INR distribution and clinical outcomes, the INR grading categories were created by 0.05 increments i.e., ≤ 0.85, 0.85--0.90, 0.90--0.95, 0.95--1.00, 1.00--1.05, 1.05--1.10, 1.10--1.15, 1.15--1.20, and \> 1.20. The adjusted OR and 95% CIs were assessed for each category using an INR value of 0.95--1.00 as the reference group. Additionally, we performed a sensitivity analysis in a subgroup of patients without intravenous (IV) recombinant tissue plasminogen activator (rtPA) treatment, because the current guidelines accept IV rtPA treatment for patients treated within 4.5 h of onset with an INR ≤ 1.7^[@bib15])^.

All analyses were conducted with SAS Version 9.2 software (SAS Institute). Two-tailed *P* values \< 0.05 were considered to be statistically significant.

Results
=======

Baseline Characteristics
------------------------

A total of 14,782 patients without anticoagulation therapy were eligible for our study (**[Supplementary Fig. 1](#F2){ref-type="fig"}**). **[Supplementary Table 1](#T4){ref-type="table"}** shows the baseline characteristics of ischemic patients included and excluded due to missing INR or 1-year follow-up. The baseline characteristics of patients included in this study and those from CNSR II were basically similar, except the patients included in this subgroup analysis for which higher prevalence of vascular risk factors including history of stroke, dyslipidemia, diabetes mellitus, coronary heart disease, and moderate or heavy drinking was noticed. More patients included in this study had a mRS score of 3--5 at discharge (**[Supplementary Table 1](#T4){ref-type="table"}**). The demographic and clinical characteristics of eligible patients are shown in **[Table 1](#T1){ref-type="table"}**. As compared with those with the low INR, the patients with high INR were more likely to be older, male, to have higher prevalence of history of stroke and coronary heart disease, pneumonia, shorter time from symptom onset to the blood sampling, higher discharge mRS score, and higher NIHSS on admission, whereas the prevalence of hypertension, diabetes mellitus, and medications (antihypertensive, antidiabetic, and lipid-lowering), and BMI were lower in patients with high INR than those with low INR.

###### Baseline characteristics of patients included vs. excluded in the study

  Characteristics                                Patients included (*n* = 14,782)   Patients excluded (*n* = 4,868)   *P*-value
  ---------------------------------------------- ---------------------------------- --------------------------------- -----------
  Age, years, mean (SD)                          64.2 (11.9)                        63.8 (11.9)                       0.05
  Male sex                                       9511 (64.3)                        3096 (63.6)                       0.35
  Vascular risk factors, *n* (%)                                                                                      
      Stroke                                     5283 (35.7)                        1599 (32.8)                       \< 0.001
      Hypertension                               11218 (75.9)                       3657 (75.1)                       0.28
      Dyslipidemia                               1844 (12.5)                        547 (11.2)                        0.02
      Diabetes mellitus                          3081 (20.8)                        947 (19.5)                        0.04
      Coronary heart disease                     1772 (12.0)                        522 (10.7)                        0.02
      Current or previous smoking                6655 (45.0)                        2184 (44.9)                       0.85
      Moderate or heavy drinkers                 4548 (30.8)                        1396 (28.7)                       0.01
  mRS score of 3--5 at discharge, *n* (%)        3076 (20.8)                        928 (19.1)                        0.01
  Body mass index, kg/m^2^, median (IQR)         24.1 (22.1--25.8)                  24.1 (22.0--25.7)                 0.38
  Time to blood collection, hour, median (IQR)   43 (24--72)                        44 (24--80)                       0.94
  Admission NIHSS score                          3 (1--6)                           3 (1--6)                          0.05
  Medications                                                                                                         
      Antihypertensive                           7242 (49.0)                        2423 (49.8)                       0.34
      Antidiabetic                               3017 (20.4)                        937 (19.2)                        0.08
      Lipid-lowering                             7848 (53.1)                        2629 (54.0)                       0.27
  Pneumonia                                      868 (5.9)                          275 (5.6)                         0.56

Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

###### Baseline characteristics of the participants to the study classified based on the admission INR value

  Characteristics                                     Total               INR \< 0.9          INR = 0.9.1.1       INR \> 1.1          *P*-value
  --------------------------------------------------- ------------------- ------------------- ------------------- ------------------- -----------
  Age, years, mean (SD)                               64.2 (11.9)         61.8 (11.2)         64.3 (11.9)         66.2 (12.0)         \< 0.001
  Male                                                9511 (64.3)         1243 (58.2)         6863 (64.7)         1432 (68.8)         \< 0.001
  INR, mean (SD)                                      1.01 (0.18)         0.85 (0.05)         0.99 (0.06)         1.26 (0.33)         \< 0.001
  ALT, U/L, median (IQR)                              19 (13--27)         20 (14--29)         18 (13--26)         18 (13--26)         \< 0.001
  AST, U/L, median (IQR)                              21 (17--26)         21 (17--27)         20 (17--26)         21 (17--28)         \< 0.001
  Vascular risk factors, *n* (%)                                                                                                      
      Stroke                                          5283 (35.7)         696 (32.6)          3812 (36.1)         775 (37.2)          0.003
      Hypertension                                    11218 (75.9)        1661 (77.7)         8033 (76.0)         1524 (73.2)         0.002
      Dyslipidemia                                    1844 (12.5)         276 (12.9)          1319 (12.5)         249 (12.0)          0.64
      Diabetes mellitus                               3081 (20.8)         506 (23.7)          2221 (21.0)         354 (17.0)          \< 0.001
  Coronary heart disease                              1772 (12.0)         242 (11.3)          1252 (11.9)         278 (13.4)          0.09
      Current or previous smoking                     6655 (45.0)         923 (43.2)          4770 (45.2)         962 (46.2)          0.72
      Moderate or heavy drinkers                      4548 (30.8)         632 (29.6)          3273 (31.0)         642 (30.8)          0.46
  Discharge mRS score = 3--5, *n* (%)                 3076 (20.8)         351 (16.4)          2213 (21.0)         512 (24.6)          \< 0.001
  BMI, kg/m^2^, median (IQR)                          24.1 (22.1--25.8)   24.1 (22.3--26.0)   24.1 (22.2--25.8)   23.8 (21.7--25.6)   \< 0.001
  Mean time to blood collection, hour, median (IQR)   43 (24--72)         45 (25--84)         43 (24--72)         40 (24--71)         \< 0.001
  Admission NIHSS score, median (IQR)                 3 (1--6)            3 (1--5)            3 (1--6)            4 (17)              \< 0.001
  Medications, *n* (%)                                                                                                                
      Antiplatelet                                    12249 (82.9)        1871 (87.6)         8642 (81.8)         1736 (83.4)         \< 0.001
  Antihypertensive                                    7242 (49.0)         1081 (50.6)         5202 (49.2)         959 (46.1)          0.008
  Antidiabetic                                        3017 (20.4)         516 (24.1)          2192 (20.8)         309 (14.8)          \< 0.001
      Lipid-lowering                                  7848 (53.1)         1286 (60.2)         5626 (53.3)         936 (45.0)          \< 0.001
  Pneumonia, *n* (%)                                  868 (5.9)           82 (3.8)            585 (5.5)           201 (9.7)           \< 0.001

Abbreviations IN-international normalized ratio, ALT-alanine transaminase, AST-aspartate transaminase, mRS-modified Rankin Scale, NIHSS-National Institutes of Health Stroke Scale.

One-Year Rates of Adverse Stroke Outcomes
-----------------------------------------

**[Table 2](#T2){ref-type="table"}** summarizes the 1-year incidences of stroke outcomes including all-cause death, stroke recurrence, composite outcome of death and stroke recurrence, and poor functional outcome. Of 14,782 patients with stroke, all-cause death occurred in 1080 (7.3%), recurrence stroke in 538 (3.9%), combined end point in 1319 (8.9%), and poor functional outcome in 3001 (20.3%). The incidence of all outcomes increased in INR groups (*P* \< 0.001 for all). The incidence of both ischemic stroke and intracranial hemorrhage also increased in INR groups (*P* \< 0.001 for ischemic stroke, *P* = 0.01 for intracranial hemorrhage). **[Supplementary Fig. 2](#F3){ref-type="fig"}** displays 1-year events rate in INR grading categories. The risk of all-cause death, recurrent stroke, combined end point, and poor functional outcome was obviously increased for the INR grading category of 1.05--1.10 and higher.

###### Events rate at 1 year in participants classified based on the admission INR value

  Outcomes                  Total               INR \< 0.9        INR = 0.9--1.1      INR \> 1.1        *P*-value
  ------------------------- ------------------- ----------------- ------------------- ----------------- -----------
  All-cause death           1080/14767 (7.3)    99/2136 (4.6)     713/10551 (6.8)     268/2080 (12.9)   \< 0.001
  Recurrent Stroke          538/13788 (3.9)     50/2030 (2.5)     380/9907 (3.8)      108/1851 (5.8)    \< 0.001
  Ischemic Stroke           510/13788 (3.7)     47/2030 (2.3)     365/9907 (3.7)      98/1851 (5.3)     \< 0.001
  Intracranial hemorrhage   28/13788 (0.2)      3/2030 (0.2)      15/9907 (0.2)       1 /1851 (0.5)     0.01
  Combined end point        1319/14782 (8.9)    121/2137 (5.7)    889/10563 (8.4)     309/2082 (14.8)   \< 0.001
  Poor functional outcome   3001/14767 (20.3)   315/2136 (14.7)   2114/10551 (20.0)   572/2080 (27.5)   \< 0.001

Abbreviations INR - international normalized ratio.

![Rates of one-year events among patients with ischemic stroke or TIA according to INR grading category](jat-26-378-g003){#F3}

Association between INR and Clinical Outcomes
---------------------------------------------

**[Table 3](#T3){ref-type="table"}** shows the associations between the INR groups and all stroke outcomes. The adjusted ORs with 95% CIs for high vs medium INR were 1.58 (1.32--1.98) for all-cause death, 1.40 (1.10--1.79) for stroke recurrence, 1.52 (1.29--1.79) for combined end point, and 1.21 (1.06--1.39) for poor functional outcome. The adjusted ORs with 95% CIs for low vs medium INR were 0.93 (0.73--1.19) for all-cause mortality, 0.80 (0.58--1.09) for stroke recurrence, 0.87 (0.70--1.07) for combined end point, and 0.89 (0.76--1.04) for poor functional outcome.

###### ORs and 95% CIs for risk of events according to admission INR value in patients with acute cerebrovascular events

                            INR \< 0.9          INR = 0.9--1.1   INR \> 1.1
  ------------------------- ------------------- ---------------- -------------------
  All-cause death                                                
      Unadjusted            0.67 (0.54--0.83)   1.00             2.04 (1.76--2.37)
      Adjusted              0.93 (0.73--1.19)   1.00             1.58 (1.32--1.89)
                                                                 
  Recurrent stroke                                               
      Unadjusted            0.63 (0.47--0.85)   1.00             1.55 (1.25--1.94)
      Adjusted              0.80 (0.58--1.09)   1.00             1.40 (1.10--1.79)
                                                                 
  Combined end point                                             
      Unadjusted            0.69 (0.61--0.79)   1.00             1.51 (1.36--1.69)
      Adjusted              0.87 (0.70--1.07)   1.00             1.52 (1.29--1.79)
                                                                 
  Poor functional outcome                                        
      Crude                 0.69 (0.61--0.79)   1.00             1.51 (1.36--1.69)
      Adjusted              0.89 (0.76--1.04)   1.00             1.21 (1.06--1.39)

Adjusted for age, sex, history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, moderate or heavy alcohol consumption, BMI, liver function, admission NIHSS, mRS scores at discharge, pneumonia, antiplatelet, antihypertensive, antidiabetic and lipid-lowing therapy, and mean time from onset to the blood sampling.

**[Fig. 1](#F1){ref-type="fig"}** shows that the adjusted ORs for all-cause death for INR grading category of 1.05--1.10, 1.10--1.15, 1.15--1.20, and \> 1.2 were 1.44 (95% CIs, 1.12--1.85), 1.71 (95% CIs, 1.27--2.31), 2.08 (95% CIs, 1.48--2.92), and 1.60 (95% CIs, 1.18--2.18), respectively. The adjusted ORs for combined end point were 1.27 (95% CIs, 1.01--1.59), 1.59 (95% CIs, 1.21--2.07), 1.90 (95% CIs, 1.40--2.57), and 1.49 (95% CIs, 1.13--1.96), respectively.

![ORs (95% CIs) for all-cause death, stroke recurrence, combined end point of recurrent stroke or death, and poor functional outcome at 1 year according to the level of INR based on a 0.05 increment, with INR of 0.95--1.00 serving as the reference group among patients with ischemic cerebrovascular events.](jat-26-378-g001){#F1}

Sensitivity Analysis
--------------------

The data listed in **[Supplementary Table 2](#T5){ref-type="table"}** shows that the high INR (\> 1.1) was independent of all the stroke outcomes in the subgroup of patients without IV rtPA treatment, which was consistent with the primary analysis. The multivariable analysis showed that the ORs with 95% CIs for the high vs medium INR were 1.61(1.34--1.95) for all-cause death, 1.46 (1.14--1.87) for stroke recurrence, 1.55 (1.31--1.83) for combined end point, and 1.25 (1.08--1.44) for poor functional outcome. No association between low INR (\< 0.9) and any stroke outcomes was found compared with the medium group.

###### Adjusted odds ratios and 95% confidence intervals for risk of events according to admission INR value in patients without rtPA treatment

                       INR groups                 
  -------------------- ------------------- ------ -------------------
  All-cause death      0.97 (0.75--1.25)   1.00   1.61(1.34--1.95)
  Recurrent stroke     0.85 (0.62--1.16)   1.00   1.46 (1.14--1.87)
  Combined end point   0.88 (0.71--1.11)   1.00   1.55 (1.31--1.83)
  Functional outcome   0.93 (0.79--1.10)   1.00   1.25 (1.08--1.44)

Adjusted for age, sex, history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, moderate or heavy alcohol consumption, body mass index, liver function, admission NIHSS, mRS scores at discharge, pneumonia, antiplatelet, antihypertensive, antidiabetic, lipid-lowing therapy and mean time from onset to blood collection.

Discussion
==========

In this post hoc analysis of the national cohort study of stroke, it was observed that the high INR is associated with increased risk of 1-year all-cause mortality, stroke recurrence, the combined end point, and poor functional outcome compared with medium INR. However, the low INR did not have a significant impact on the all stroke outcomes. In INR grading categories, only relationships between the all-cause death and combined end point with the elevated grading increment of INR remained significant, although the rates of all stroke outcomes increased with the increase in INR increment. To the best of our knowledge, this is the first national study that defines the prognostic value of baseline INR in patients with ischemic cerebrovascular events.

It was noticed that compared with median INR, the high INR was significantly associated with the high risk of 1-year stroke outcomes including all-cause mortality, stroke recurrence, combined end point, and poor functional outcome. In previously published studies, the association between elevated baseline INR and poor outcomes in patients with acute decompensated heart failure and acute pulmonary embolism was investigated^[@bib10],\ [@bib11])^. A plausible explanation for this phenomenon might be that after an ischemic event, the activation of the coagulation system may result in the consumption of coagulation factors, which is manifested as an elevated INR. Therefore, the thrombosis could be inhibited. In this conditions, either the blood clot enlargement is prevented or thrombolysis is stimulated to increase the blood flow perfusion to the distal vessel in patients after stroke onset^[@bib16])^. In this analysis, the patients with higher INR had a more serious stroke measured by the baseline NIHSS score (**[Supplementary Table 3](#T6){ref-type="table"}**). Our results suggest that the admission INR would be an important index for prognosis in stroke patients and might be a therapeutic target in those without AF.

###### Associations between INR and baseline patient characteristics using the ordinal logistic regression model

  Characteristics                       Odds ratios   95% confidence intervals   *P*-value
  ------------------------------------- ------------- -------------------------- -----------
  Age, years                                                                     
  ≥ 65 vs. \< 65                        1.50          1.39--1.61                 \< 0.001
  Female vs. male                       0.71          0.65--0.78                 \< 0.001
  Vascular risk factors                                                          
      Stroke                            1.08          1.00--1.17                 0.046
      Hypertension                      0.86          0.79--0.93                 \< 0.001
      Dyslipidemia                      0.99          0.89--1.10                 0.80
      Diabetes mellitus                 0.81          0.74--0.89                 \< 0.001
      Coronary heart disease            1.08          0.97--1.20                 0.18
      Current or previous smoking       0.93          0.85--1.01                 0.10
      Moderate or heavy drinkers        1.02          0.94--1.11                 0.66
  Body mass index                       0.99          0.98--1.00                 0.17
  Mean time to blood collection, days   0.96          0.94--0.98                 \< 0.001
  Admission NIHSS score                 1.03          1.02--1.04                 \< 0.001

Ordinal logistic regression model was used to evaluate association of INR with baseline patient characteristics. INR was divided into three categories: low INR (\< 0.9), medium INR group (0.9--1.1), high INR (\>1.1). Abbreviations: INR, international normalized ratio; NIHSS, National Institutes of Health Stroke Scale.

It was also found a high risk of all-cause death and combined end point in patients with INR grading category \> 1.05, with 0.05 increments, as compared with those with INR from 0.95 to 1.00. This result supports the feasibility of considering INR, divided in three groups, for patients with ischemic cerebrovascular events. Yet, no significant association between INR value and stroke recurrence or poor functional outcome was observed. This could be explained by the relative few events occurring in each group, which could enlarge the confidence interval.

In addition, a low INR had a minor risk reduction in all stroke outcomes. As compared with INR of 0.95--1.00, none of low INR grading categories was meaningfully associated with any stroke outcomes. The reason for this phenomenon is that the baseline INR was barely increased, because the activation of anticoagulation system was low after minor ischemic cerebrovascular events onset. However, another unknown mechanism cannot be excluded to interpret this result.

It should be recognized that this study had some limitations, which are listed in the following. First, it was an observational study, which limited the possibility to make causal inferences. Secondly, the diffusion-weighted imaging lesion volume measurements were not performed to determine the relationship between INR and brain infarct size. Thus, the association between INR and cerebral infarct size was not considered in this study. Thirdly, the association between INR and outcomes based on the subtypes of ischemic stroke was not evaluated, because there are no data on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) subtypes or other classification of ischemic stroke subtypes. Furthermore, the patients with cardioembolic stroke were excluded from the current study due to the treatment with anticoagulant drugs. Finally, our cohort included exclusively Chinese patients. Hence, the results may not be generalized to other ethnic populations with cerebrovascular events.

Conclusions
===========

In patients with acute ischemic stroke, increased baseline INR in the absence of anticoagulation was an independent predictor of 1-year all-cause mortality, stroke recurrence, combined end point, and poor functional outcome. These findings might suggest the importance of INR evaluation in clinical practice in acute ischemic stroke patients both with and without preadimission anticoagulant use. Nevertheless, further investigation would be necessary to verify and confirm the relationship between INR and clinical outcomes of stroke.
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